Food ingredients and lipid mediators

Current Nutrition and Food Science

Volumn 3, Issue 4, 2007, Pages 255-276

  Nomikos, Tzortzis ^a   Fragopoulou, Elizabeth ^a   Antonopoulou, Smaragdi ^a,b  

^a HAROKOPIO UNIVERSITY   (Greece)

^b NONE   (Greece)

Author keywords

Food ingredients; Inflammation; Lipid mediators; Nutrition; Platelet activating factor; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CURCUMIN; DOCOSAHEXAENOIC ACID; ENDOCANNABINOID; FLAVONOL DERIVATIVE; GINKGOLIDE B; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; ICOSAPENTAENOIC ACID; LEUKOTRIENE; LIPID; LIPOXIN; LYCOPENE; OMEGA 3 FATTY ACID; ORGANOSULFUR DERIVATIVE; PHENOL DERIVATIVE; PHOSPHOLIPID; PHYTOESTROGEN; PHYTOSTEROL; POLYPHENOL DERIVATIVE; PROSTAGLANDIN; RESVERATROL; RETINOL; SPHINGOLIPID; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNINDEXED DRUG; VITAMIN;

ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BIOCHEMISTRY; BIOSYNTHESIS; CANCER; CARDIOVASCULAR DISEASE; CATABOLISM; CELL FUNCTION; DIABETES MELLITUS; DIETARY FIBER; DRUG MECHANISM; FOOD COMPOSITION; FOOD INTAKE; HUMAN; IN VITRO STUDY; METABOLISM; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 36248994070     PISSN: 15734013     EISSN: None     Source Type: Journal    
DOI: 10.2174/1573401310703040255     Document Type: Review

References (238)

1. Seeds MC, Bass DA. Regulation and metabolism of arachidonic acid. Clin Rev Allergy Immunol 1999; 17(1-2): 5-26.
2. Cabral GA. Lipids as bioeffectors in the immune system. Life Sci 2005; 77(14): 1699-710.
3. Diaz BL, Arm JP. Phospholipase A(2). Prostaglandins Leukot Essent Fatty Acids 2003; 69(2-3): 87-97.
4. Triggiani M, Granata F, Giannattasio G, Marone G. Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. J Allergy Clin Immunol 2005; 116(5): 1000-6.
5. Calder PC. Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 2006; 75(3): 197-202.
6. Fitzpatrick FA. Cyclooxygenase enzymes: regulation and function. Curr Pharm Des 2004; 10(6): 577-588.
7. Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003; 65(2): 153-9.
8. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004; 103(2): 147-166.
9. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294(5548): 1871-5.
10. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: under-appreciated mediators of innate immune responses. J Immunol 2005; 174(2): 589-594
11. Back M. Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sci 2002; 71(6): 611-622.
12. Sharma JN, Mohammed LA. The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets? Inflammopharmacology 2006; 14(1-2): 10-16.
13. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006; 58(3): 375-388.
14. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 2005; 73(3-4): 141-162.
15. Roman RJ, Maier KG, Sun CW, Harder DR, Alonso-Galicia M. Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol 2000; 27(11): 855-865.
16. Carroll MA, McGiff JC. A new class of lipid mediators: cytochrome P450 arachidonate metabolites. Thorax 2005: 55 (Suppl 2): S13-6.
17. Bradshaw AB, Walker JM. The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol 2005; 144(4): 459-465.
18. Das UN. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot Essent Fatty Acids 2000; 63(6): 351-362.
19. Serhan CN. Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr Opin Clin Nutr Metab Care 2005; 8(2): 115-121.
20. Wang X, Devaiah SP, Zhang W, Welti R. Signaling functions of phosphatidic acid. Prog Lipid Res 2006; 45(3): 250-278.
21. Ninio E. Phospholipid mediators in the vessel wall: involvement in atherosclerosis. Curr Opin Clin Nutr Metab Care 2005; 8(2): 123-131.
22. Tokumura A. Metabolic pathways and physiological and pathological significances of lysolipid phosphate mediators. J Cell Biochem 2004; 92(5): 869-881.
23. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004; 73: 321-354.
24. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 2006; 12(1):RA5-16.
25. Won JS, Singh I. Sphingolipid signaling and redox regulation. Free Radic Biol Med 2006; 40(11): 1875-1888.
26. Chalfant CE, Spiegel S. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci 2005; 118(Pt20): 4605-4612.
27. Pratico D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine. Trends Endocrinol Metab 2001; 12(6): 243-7.
28. Marathe GK, Harrison KA, Murphy RC, Prescott SM, Zimmerman GA, McIntyre TM. Bioactive phospholipid oxidation products. Free Radic Biol Med 2000; 28(12): 1762-1770.
29. Bjorkhem I, Diczfalusy U. Oxysterols: friends, foes, or just fellow passengers? Arterioscler Thromb Vasc Biol 2002; 22(5): 734-742.
30. Bochkov VN, Leitinger N. Anti-inflammatory properties of lipid oxidation products. J Mol Med 2003; 81(10):613-626.
31. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002; 21(6): 495-505.
32. Roland I, De Leval, X, Evrard B, Pirotte B, Dope JM, Delattre L. Modulation of the arachidonic cascade with omega3 fatty acids or analogues: potential therapeutic benefits. Mini Rev Med Chem 2004; 4(6):659-668.
33. Serhan CN. Novel omega - 3-derived local mediators in anti-inflammation and resolution. Pharmacol Ther 2005; 105(1): 7-21.
34. Yaqoob P. Fatty acids and the immune system: from basic science to clinical applications. Proc Nutr Soc 2004; 63(1): 89-104.
35. Barham JB, Edens MB, Fonteh AN, Johnson MM, Easter L, Chilton FH. Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr 2000; 130(8):1925-1931.
36. Hardman WE. (n-3) fatty acids and cancer therapy. J Nutr 2004; 134(12 Suppl): 3427S-3430S.
37. Wong KW. Clinical efficacy of n-3 fatty acid supplementation in patients with asthma. J Am Diet Assoc 2005; 105(1): 98-105.
38. Di M, V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410(6830): 822-5.
39. Breslow JL. n-3 fatty acids and cardiovascular disease. Am J Clin Nutr 2006; 83(6 Suppl): 1477S-1482S.
40. Fan YY, Chapkin RS. Importance of dietary gamma-linolenic acid in human health and nutrition. J Nutr 1998; 128(9): 1411-4.
41. Bassaganya-Riera J, Hontecillas R, Beitz DC. Colonic anti-inflammatory mechanisms of conjugated linoleic acid. Clin Nutr 2002; 21(6): 451-9.
42. Parodi PW. Cow's milk fat components as potential anticarcinogenic agents. J Nutr 1997; 127(6): 1055-1060.
43. Rodriguez-Cabezas ME, Galvez J, Camuesco D, et al. Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Chn Nutr 2003; 22(5): 463-471.
44. Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res 2005; 49(6): 601-8.
45. Yang L, Mutanen M, Cheng Y, Duan R. Effects of red meat and fiber in high fat diet on activities of sphingomyelinase, ceramidase and caspase-3 in rat colonic mucosa. J Nutr Biochem 2002; 13(8): 499.
46. Cheng Y, Ohlsson L, Duan RD. Psyllium and fat in diets differentially affect the activities and expressions of colonic sphingomyelinases and caspase in mice, Br J Nutr 2004; 91(5): 715-723.
47. Fawzy AA, Vishwanath BS, Franson RC. Inhibition of human non-pancreatic phospholipases A2 by retinoids and flavonoids. Mechanism of action. Agents Actions 1988; 25(34): 394-400.
48. Kim BH, Kang KS, Lee YS. Effect of retinoids on LPS-induced COX-2 expression and COX-2 associated PGE(2) release from mouse peritoneal macrophages and-TNF-alpha release from rat peripheral blood mononuclear cells. Toxicol Lett 2004; 150(2): 191-201.
49. Kozawa O, Suzuki A, Shinoda J, Oiso Y. Effect of retinoic acid on prostaglandin F2 alpha-induced phospholipase D activity in osteoblast-like cells. Prostaglandins Leukot Essent Fatty Acids 1996; 55(3): 151-4.
50. Delage B, Bairras C, Buaud B, Pallet V, Cassand P. A high-fat diet generates alterations in nuclear receptor expression: prevention by vitamin A and links with cyclooxygenase-2 and beta-catenin. Int J Cancer 2005; 116(6): 839-846.
51. Zingg JM, Azzi A. Non-antioxidant activities of vitamin E. Curr Med Chem 2004; 11(9): 1113-1133.
52. Jiang Q, Ames BN. Gamma-tocopherol, but not alpha-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J, 2003; 17(8): 816-822.
53. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Does vitamin E supplementation modulate in vivo arachidonate metabolism in human inflammation? Pharmacol Toxicol 1987; 61(4): 246-9.
54. Luostarinen R, Siegbahn A, Saldeen T. Effects of dietary supplementation with vitamin E on human neutrophil chemotaxis and generation of LTB4. Ups J Med Sci 1991; 96(2): 103-111.
55. Silbert PL, Leong LL, Sturm MJ, Strophair J, Taylor RR. Short term vitamin E supplementation has no effect on platelet function, plasma phospholipase A2 and lyso-PAF in male volunteers. Clin Exp Pharmacol Physiol 1990; 17(9):645-651.
56. Eskew ML, Zarkower A, Scheuchenzuber WJ, et al. Effects of inadequate vitamin E and/or selenium nutrition on the release of arachidonic acid metabolites in rat alveolar macrophages. Prostaglandins 1989; 38(1):79-89.
57. Lomnitski L, Bergman M, Schon I, Grossman S. The effect of dietary vitamin E and beta-carotene on oxidation processes in the rat testis. Biochim Biophys Acta 1991; 1082(1): 101-7.
58. Azzi A. The role of alpha-tocopherol in preventing disease. Eur J Nutr 2004; 43 (Suppl 1): I/18-I/25.
59. Wu D, Hayek MG, Meydani S. Vitamin E and macrophage cyclooxygenase regulation in the aged. J Nutr 2001; 131(2): 382S-388S.
60. Jiang Q, Christen S, Shigenaga MK, Ames BN. gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr 2001; 74(6): 714-722.
61. Bianchini F, Vainio H. Allium vegetables and organosulfur compounds: do they help prevent cancer? Environ Health Perspect 2001; 109(9): 893-902.
62. Tapiero H, Townsend DM, Tew KD. Organosulfur compounds from alliaceae in the prevention of human pathologies. Biomed Pharmacother 2004; 58(3): 183-193.
63. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2000; 130(8S Suppl): 2073S-2085S.
64. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000; 52(4): 673-751.
65. de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent mechanisms and clinical implications. Mol Nutr Food Res 2005; 49(5): 405-430.
66. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 2005; 16(8): 449-466.
67. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade-eicosanoids, cyclooxygenases, and lipoxygenases-as an adjunct in cancer therapy. Integr Cancer Ther 2002; 1(1): 7-37.
68. Formica JV, Regelson W. Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol 1995; 33(12): 1061-1080.
69. Surh YJ. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a short review. Food Chem Toxicol 2002; 40(8): 1091-7.
70. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005; 41(13): 1955-1968.
71. Kris-Etherton PM, Hecker KD, Bonanome A et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 2002; 113 (Suppl 9B): 71S-88S.
72. Sies H, Schewe T, Heiss C, Kelm M. Cocoa polyphenols and inflammatory mediators. Am J Clin Nutr 2005; 81(1 Suppl): 304S-312S.
73. Matsuo N, Yamada K, Mori M et al. Inhibition by dietary tea polyphenols of chemical mediator release from rat peritoneal exudate cells. Biosci Biotechnol Biochem 2000; 64(7): 1437-1443.
74. Schewe T, Sadik C, Klotz LO, Yoshimoto T, Kuhn H, Sies H. Polyphenols of cocoa: inhibition of mammalian 15-lipoxygenase. Biol Chem 2001; 382(12):1687-1696.
75. Kim, SY, Ahn BH, Kim J, et al. Phospholipase C, protein kinase C, Ca2+/calmodulin-dependent protein kinase II, and redox state are involved in epigallocatechin gallate-induced phospholipase D activation in human astroglioma cells. Eur J Biochem 2004; 271(17): 3470-3480.
76. Yang JA, Choi JH, Rhee SJ. Effects of green tea catechin on phospholipase A2 activity and antithrombus in streptozotocin diabetic rats. J Nutr Sci Vitaminol (Tokyo) 1999; 45(3). 337-346.
77. Rhee SJ, Choi JH, Park MR. Green tea catechin improves microsomal phospholipase A2 activity and the arachidonic acid cascade system in the kidney of diabetic rats. Asia Pac J Clin Nutr 2002; 11(3): 226-231.
78. Hussain T, Gupta S, Adhami VM, Mukhtar H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer 2005; 113(4): 660-9.
79. Peng G, Dixon DA, Muga SJ, Smith TJ, Wargovich MJ. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol Carcinog 2006; 45(5): 309-319.
80. Petroni A, Blasevich M, Salami M, Papini N, Montedoro, GF, Galli C. Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. Thromb Res 1995; 78(2): 151-160.
81. Kohyama N, Nagata, T, Fujimoto S, Sekiya K. Inhibition of arachidonate lipoxygenase activities, by 2-(3,4-dihydroxyphenyl)ethanol, a phenolic compound from olives. Biosci Biotechnol Biochemn 1997; 61(2): 347-350.
82. Maiuri MC, De Stefano D, Di Meglio P, et al. Hydroxytyrosol, a phenolic compound from virgin olive oil, prevents macrophage activation. Naunyn Schmiedebergs Arch Pharmacol 2005; 371(6): 457-465.
83. de la PR, Ruiz G, V, Hoult JR. Inhibition of leukocyte 5-lipoxygenase by phenolics from virgin olive oil Biochem Pharmacol 1999; 57(4): 445-9.
84. Beauchamp GK, Keast RS, Morel D, et al. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature 2005; 437(7055): 45-46.
85. Visioli F, Caruso D, Grande S, et al. Virgin Olive Oil Study (VOLOS): vasoprotective potential of extra virgin olive oil in mildly dyslipidemic patients. Eur J Nutr 2005; 44(2): 121-7.
86. Kim BH, Chung EY, Ryu JC, Jung SH, Min KR, Kim Y. Anti-inflammatory mode of isollavone glycoside sophoricoside by inhibition. of interleukin-6 and cyclooxygenase-2 in inflammatory response. Arch Pharm Res 2003; 26(4): 306-311.
87. Garcia-Martinez MC, Hermenegildo C, Tarin JJ, Cano A. Phytoestrogens increase the capacity of scrum to stimulate prostacyclin release in human endothelial cells. Acta Obstet Gynecol Scand 2003; 82(8): 705-710.
88. Vera R, Galisteo M, Villar IC, et al. Soy isoflavones improve endothelial function in spontaneously hypertensive rats in an estrogen-independent manner: role of nitric-oxide synthase, superoxide, and cyclooxygenase metabolites. J Pharmacol Exp Ther 2005; 314(3): 1300-1309.
89. Garrido A, De la Maza MP, Hirsch S, Valladares L. Soy isoflavones affect platelet thromboxane A2 receptor density but not plasma lipids in menopausal women. Maturitas 2006; 54(3): 270-6.
90. Murakami A, Takahashi D, Hagihara K, Koshimizu K, Ohigashi H. Combinatorial effects of nonsteroidal anti-inflammatory drugs and food constituents on production of prostaglandin E2 and tumor necrosis factor-alpha in RAW264.7 murine macrophages. Biosci Biotechnol Biochem. 2003; 67(5): 1056-1062.
91. Hwang JT, Ha J, Park OJ. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 2005; 332(2): 433-440.
92. Moreno JJ. Effect of olive oil minor components, on oxidative stress and arachidonic acid mobilization and metabolism by macrophages RAW 264.7. Free Radio Biol Med 2003; 35(9): 1073-1081.
93. Awad AB, Toczek J, Fink CS. Phytosterols decrease prostaglandin release in cultured P388D1/MAB macrophages. Prostaglandins Leukot Essent Fatty Acids 2004; 70(6): 511-20.
94. Awad AB, von Holtz RL, Cone JP, Fink CS, Chen YC. beta-Sitosterol inhibits growth of HT-29 human colon cancer cells by activating the sphingomyelin cycle. Anticancer Res 1998; 18(1A): 471-3.
95. Paterson TJ, Baxter G, Lawrence J, Duthie G. Is there a role for dietary salicylates in health? Proc Nutr Soc, 2006; 65(1): 93-6.
96. Harris RC. Cyclooxygenase-2 and the kidney: functional and pathaphysiological implications. J Hypertens Suppl 2002; 20(6): S3-9.
97. Mickleborough TD, Gotshall RW, Rhodes J, Tucker A, Cordain L. Elevating dietary salt exacerbates hyperpnea-hiduced airway obstruction in guinea pigs. J Appl Physiol 2001; 91(3): 1061-6.
98. Mickleborough TD, Lindley MR, Ray S. Dietary salt airway inflammation, and diffusion capacity in exercise-induced asthma. Med Sci Sports Exerc 2005; 37(6): 904-914.
99. Hanada K, Mitsuhashi Y, Hashimoto I. Inhibitory effect of the leukotriene B4 receptor antagonist against hypomagnesic diet-induced dermatitis in hairless rats. J Dermatol 1992; 19(8): 456-60.
100. Faure P, Durand P, Blache D, Favier A, Roussel AM. Influence of a longterm zinc-deficient diet on rat platelet function and fatty acid composition. Biometals 1995; 8(1): 80-5.
101. Fong LY, Zhang L, Jiang Y, Farber JL. Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats. J Natl Cancer Inst 2005; 97(1): 40-50.
102. Arthur JR, McKenzie RC, Beckett GJ. Selenium in the immune system. J Nutr 2003; 133(5 SuppI 1): 1457S-1459S.
103. Alaejos MS, Diaz Romero FJ, Diaz RC. Selenium and cancer: some nutritional aspects. Nutrition 2000; 16(5): 376-383.
104. Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem 1979; 254(19): 9355-8.
105. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30(5 Suppl): S294-301.
106. Snyder F. Platelet-activating factor: the biosynthetic and catabolic enzymes. Biochem J 19915; 305 ( Pt 3): 689-705.
107. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000; 80(4): 1669-1699.
108. Balestrieri, ML, Servillo L, Lee T. The role of platelet-activating factor-dependent transacetylase in the biosynthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by stimulated endothelial cells. J Biol Chem 1997; 272(28): 17431-7.
109. Snyder F, Lee TC, Blank ML. The role of transacylases in the metabolism of aracbidonate and platelet activating factor. Prog Lipid Res 1992; 31(1): 65-86.
110. Winkler ID, Sung CM, Hubbard WC, Chilton FH. Influence of arachidonic, acid on indices of phospholipase A2 activity in the human neutrophil. Biochem J 1993; 291(Pt 3): 825-831.
111. Tanaka T, Iimori M, Tsukatani H, Tokumura A. Platelet-aggregating effects of platelet-activating factor-like phospholipids formed by oxidation of phosphatidylcholmes containing an sa-2-polyunsaturated fatty acyl group. Biochim, Biophys Acts, 1994; 1210(2): 202-8.
112. Tokumura A, Toujima M, Yoshioka Y, Fukuzawa K. Lipid peroxidation in low density lipoproteins from human plasma and egg yolk promotes accumulation of 1-acyl analogues of platelet-activating factor-like lipids. Lipids 1996; 31(12): 1251-8.
113. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. J Biol Chem 1997; 272(29): 17895-8.
114. Lee TC, Uemura Y, Snyder F. A novel CoA-independent transacetylase produces the ethanolamine plasmalogen and acyl analogs of platelet-activating factor (PAF) with PAF as the acetate donor in HL-60 cells. J Biol Chem 1992; 267(28): 19992-20001.
115. Lee TC. N-acetylatiou of sphingosine by platelet-activating factor: sphingositte transacetylase. Methods Enzymol 2000; 311: 117-122.
116. Bae K, Longobardi L, Karasawa K, et al. Platelet-activating factor (PAF)-dependent transacetylase and its relationship with PAF acetylhydrolases. J Biol Chem 2000; 275(35): 26704-9.
117. Liu M, Subbaiah PV. Hydrolysis and transesterification of platelet-activating factorby lecithin-cholesterol. acyltransferase. Proc Natl Acad Sci USA 1994; 91(13): 6035-9.
118. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 2000; 69: 419-445.
119. Honda Z, Ishii S, Shimizu T. Platelet-activating factor receptor. J Biochem (Tokyo) 2002; 131(6): 773-9.
120. Izumi T, Honda Z, Mutoh H, Kume K, Shimizu T. Regulation and signal transduction of PAF receptor. Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 461-6.
121. Marrache AM, Gobed F, Zhu T, Chemtob S. Intracellular signaling of lipid mediators via cognate nuclear G protein-coupled receptors. Endothelium 2005; 12(1-2): 63-72.
122. Ihida K, Predescu, D, Czekay RP, Palade GE. Platelet activating factor receptor (PAF-R) is found in a large endosomal compartment in human umbilical vein endothelial cells. J Cell Sci 1999; 112 ( Pt 3): 285-295.
123. Shimizu T, Mutoh H. Structure and regulation of platelet activating factor receptor gene. Adv Exp Med Biol 1 ?97; 407: 197-204.
124. Mutoh H, Ishii S, Izumi.T, Kato S, Shimizu T. Platelet-activating factor (PAF) positively auto-regulates the expression of human PAF receptor transcript 1 (1eukocyte-type), through NF-kappa B. Biochem. Biophys Res Common 1994; 205(2): 1137-1142.
125. Ye RD, Kravchenko VV, Pan Z, Feng L. Stimulation of NF-kappa B activation and gene expression by platelet-activating factor. Adv Exp Med Biol 1996; 416: 143-151.
126. Pegorier S, Stengel D, Durand H, Croset M, Ninio E. Oxidized phospholipid: POVPC binds to platelet-activating-factor receptor on human macrophages. Implications in atherosclerosis. Atherosclerosis 2006; 188(2): 433-443.
127. Camussi G, Tetta C, Baglioni C. The role of platelet-activating factor in inflammation. Clin Imununol Immmunopathol 1990; 57(3): 331-8.
128. Labrakis-Lazana K, Lazanas M, Koussissis S, Tournis, S, Demopoulos CA. PAF of biological fluids in disease: blood levels in allergic rhinitis. Haematologica 1988; 73(5): 379-392.
129. Beer JH, Wuthrich B, von Felten A. Allergen exposure in acute asthma causes the release of platelet-activating fadtor (PAF) as demonstrated by the desensitization of platelets to PAF. Int Arch Allergy Immunol 1995; 106(3): 291-6.
130. Ayala A, Chaudry IH. Platelet activating factor and its role in trauma, shock, and sepsis. New Horiz 1996; 4(2): 265-275.
131. Johnson CD. Platelet-activating factor and platelet-activating factor antagonists in acute pancreatitis. Dig Surg 1999; 16(2): 93-101.
132. Nassif A, Longo WE, Mazuski JE, Vernava AM, Kaminski DL. Role of cytokines and platelet-activating factor in inflammatory bowel disease. Implications for therapy. Dis Colon Rectum 1996; 39(2): 217-223.
133. Martin T, Losa JE, Garcia-Salgado MJ, Perez-Arellano JL. The role of platelet-activating factor (PAF) in interstitial pulmonary disease. J Investig Allergol Clin Immunol 1994; 4(3): 149-157.
134. Cavallo-Perin P, Lupia E, Gruden G et al. Increased blood levels of platelet-activating factor in insulin-dependent diabetic patients with microalbuminuria. Nephrol Dial Transplant 2000; 15(7): 994-9.
135. Iatrou C, Moustakas G, Antonopoulou S, Demopoulos CA, Ziroyiannis P. Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis. Nephron 1996; 72(4): 611-6.
136. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340(2): 115-126.
137. Steinberg D. A critical look at the evidence for the oxidation of LDL in atherogenesis. Atherosclerosis 1997; 131 Suppl: S5-7.
138. Demopoulos CA, Karantonis HC, Antonopoulou S. Platelet activating factor-a molecular link between atherosclerosis theories. European Journal of Lipid Science and Technology 2003; 105(11): 705-716.
139. Takahashi S, Yoshikawa T, Naito Y, Tanigawa T, Yoshida N, Kondo M. Role of platelet-activating factor (PAF) in superoxide production by human polymorphonuclear leukocytes. Lipids 1991; 26(12): 1227-1230.
140. Gaut JP, Heinecke JW. Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc Med 2001; 11(3-4): 103-112.
141. Liapikos TA, Antonopoulou S, Karabina SP, Tsoukatos DC, Demopoulos CA, Tselepis AD. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim Biophys Acta 1994; 1212(3): 353-360.
142. Golino P, Ambrosio G, Ragni M et al. Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation. Circulation 1993; 88(3): 1205-1214.
143. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998; 91(8): 2645-2657.
144. Handley DA, Arbeeny CM, Lee ML, Van Valen RG, Saunders RN. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology 1984; 8(3-4): 137-142.
145. Koltai M, Guinot P, Hosford D, Braquet PG. Platelet-activating factor antagonists: scientific background and possible clinical applications. Adv Pharmacol 1994; 28: 81-167.
146. Summers JB, Albert DH. Platelet activating factor antagonists. Adv Pharmacol 1995; 32: 67-168.
147. Negro Alvarez JM, Miralles Lopez JC, Ortiz Martinez JL, Abellan AA, Rubio dB. Platelet-activating factor antagonists. Allergol Immunopathol (Madr) 1997; 25(5): 249-258.
148. Chang GT, Kang SK, Kim JH, Chung KH, Chang YC, Kim CH. Inhibitory effect of the Korean herbal medicine, Dae-Jo-Whan, on platelet-activating factor-induced platelet aggregation. J Ethnopharmacol 2005; 102(3): 430-9.
149. Jantan I, Rafi IA, Jalil J. Platelet-activating factor (PAF) receptor-binding antagonist activity of Malaysian medicinal plants. Phytomedicine 2005; 12(1-2): 88-92.
150. Oku H, Ueda Y, Iinuma M, Ishiguro K. Inhibitory effects of xanthones from guttiferae plants on PAF-induced hypotension in mice. Planta Med 2005; 71(1): 90-2.
151. Chang FR, Wei JL, Teng CM, Wu YC. Two new 7-dehydroaporphine alkaloids and antiplatelet action aporphines from the leaves of Annona purpurea. Phytochemistry 1998; 49(7): 2015-8.
152. Zhang SX, Chen K, Liu XJ et al. The isolation and structural elucidation of three new neolignans, piperulins [corrected] A, B, and C, as platelet activating factor receptor antagonists from Piper puberulum. J Nat Prod 1995; 58(4): 540-7.
153. Keys A. Coronary heart disease in seven countries. 1970. Nutrition 1997; 13(3): 250-2.
154. Bazzano LA, He J, Ogden LG et al. Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Am J Clin Nutr 2002; 76(1): 93-9.
155. Liu S, Lee IM, Ajani U, Cole SR, Buring JE, Manson JE. Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: The Physicians' Health Study. Int J Epidemiol 2001; 30(1): 130-5.
156. Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995; 274(2): 131-6.
157. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339(8808): 1523-6.
158. Nunez D, Randon J, Gandhi C, Siafaka-Kapadai A, Olson MS, Hanahan DJ. The inhibition of platelet-activating factor-induced platelet activation by oleic acid is associated with a decrease in polyphosphoinositide metabolism. J Biol Chem 1990; 265(30): 18330-8.
159. Sperling RI, Robin JL, Kylander KA, Lee TH, Lewis RA, Austen KF. The effects of N-3 polyunsaturated fatty acids on the generation of platelet-activating factor-acether by human monocytes. J Immunol 1987; 139(12): 4186-4191.
160. Weber C, Aepfelbacher M, Lux I, Zimmer B, Weber PC. Docosahexaenoic acid inhibits PAF and LTD4 stimulated [Ca2+]i-increase in differentiated monocytic U937 cells. Biochim Biophys Acta 1991; 1133(1): 38-45.
161. Kang JX, Man SF, Hirsh AJ, Clandinin MT. Characterization of platelet-activating factor binding to human airway epithelial cells: modulation by fatty acids and ion-channel blockers. Biochem J 1994; 303 (Pt 3):795-802.
162. Mayer K, Merfels M, Muhly-Reinholz M, et al. Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am J Physiol Heart Circ Physiol 2002; 283(2): H811-8.
163. Watanabe S, Doshi M, Akimoto K, Kiso Y, Hamazaki T. Suppression of platelet-activating factor generation and modulation of arachidonate metabolism by dietary enrichment with (n-9) eicosatrienoic acid or docosahexaenoic acid in mouse peritoneal cells. Prostaglandins Other Lipid Mediat 2001; 66(2): 109-120.
164. Pickett WC, Nytko D, Dondero-Zahn C, Ramesha C. The effect of endogenous eicosapentaenoic acid on PMN leukotriene and PAF biosynthesis. Prostaglandins Leukot Mod 1986; 23(2-3): 135-40.
165. Oh-hashi K, Takahashi T, Watanabe S, Kobayashi T, Okuyama H. Possible mechanisms for the differential effects of high linoleate safflower oil and high alpha-linolenate perilla oil diets on platelet-activating factor production by rat polymorphonuclear leukocytes. J Lipid Mediat Cell Signal 1997; 17(3): 207-220.
166. Horii T, Satouchi K, Kobayashi Y, et al. Effect of dietary alpha-linolenate on platelet-activating factor production in rat peritoneal polymorphonuclear leukocytes. J Immunol 1991; 147(5): 1607-1613.
167. Chilton FH, Patel M, Fonteh AN, Hubbard WC, Triggiani M. Dietary n-3 fatty acid effects on neutrophil lipid composition and mediator production. Influence of duration and dosage. J Clin Invest 1993; 91(1): 115-122.
168. Triggiani M, Connell TR, Chilton FH. Evidence that increasing the cellular content of eicosapentaenoic acid does not reduce the biosynthesis of platelet-activating factor. J Immunol 1990; 145(7): 2241-8.
169. Hanel AM, Schuttel S, Gelb MH. Processive interfacial catalysis by mammalian 85-kilodalton phospholipase A2 enzymes on product-containing vesicles: application to the determination of substrate preferences. Biochemistry 1993; 32(23): 5949-5958.
170. Shikano M, Masuzawa Y, Yazawa K, Takayama K, Kudo I, Inoue K. Complete discrimination of docosahexaenoate from arachidonate by 85 kDa cytosolic phospholipase A2 during the hydrolysis of diacyl- and alkenylacylglycerophosphoethanolamine. Biochim Biophys Acta 1994; 1212(2): 211-6.
171. Blank ML, Smith ZL, Cress EA, Snyder F. Molecular species of ethanolamine plasmalogens and transacylase activity in rat tissues are altered by fish oil diets. Biochim Biophys Acta 1994; 1214(3): 295-302.
172. Yeo YK, Philbrick DJ, Holub BJ. The effect of long-term consumption of fish oil on platelet-activating factor synthesis in rat renal microsomes. Biochem Biophys Res Commun 1989; 160(3): 1238-1242.
173. Oh-hashi K, Takahashi T, Tanabe A, Watanabe S, Okuyama H. Dietary alpha-linolenate suppresses endotoxin-induced platelet-activating factor production in rat kidney. Lipids 1999; 34(1): 31-7.
174. Akisu M, Huseyinov A, Baka M, Yalaz M, Kultursay N. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the generation of platelet-activating factor and leukotriene B4 in hypoxic-ischemic brain in young mice. Prostaglandins Leukot Essent Fatty Acids 2002; 67(6): 429-433.
175. Akisu M, Baka M, Coker I, Kultursay N, Huseyinov A. Effect of dietary n-3 fatty acids on hypoxia-induced necrotizing enterocolitis in young mice. n-3 fatty acids alter platelet-activating factor and leukotriene B4 production in the intestine. Biol Neonate 1998; 74(1): 31-8.
176. Ingram AJ, Parbtani A, Clark WF, et al. Effects of flaxseed and flax oil diets in a rat-5/6 renal ablation model. Am J Kidney Dis 1995; 25(2): 320-9.
177. Hall AV, Parbtani A, Clark WF, et al. Abrogation of MRL/lpr lupus nephritis by dietary flaxseed. Am J Kidney Dis 1993; 22(2): 326-332.
178. Karantonis HC, Antonopoulou S, Perrea DN, et al. In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits. Nutr Metab Cardiovasc Dis 2006; 16(3): 174-185.
179. Karantonis HC, Antonopoulou S, Perrea DN, et al. Biological effects of lipids from olive oil and olive pomace, in early atherosclerosis development. Implication of Platelet Activating Factor (PAF). 2nd International conference, Traditional Mediterranean Diet: Past Present and Future 2005.
180. Sperling RI. Dietary omega-3 fatty acids: effects on lipid mediators of inflammation and rheumatoid arthritis. Rheum Dis Clin North Am 1991; 17(2): 373-389.
181. Arm JP, Lee TH. The use of fish oil in bronchial asthma. Allergy Proc 1989; 10(3): 185-7.
182. Grimminger F, Mayser P, Papavassilis C, et al. A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile. Clin Investig 1993; 71(8): 634-643.
183. Clark WF, Parbtani A. Omega-3 fatty acid supplementation in clinical and experimental lupus nephritis. Am J Kidney Dis 1994; 23(5): 644-7.
184. Clark WF, Parbtani A, Huff MW, et al. Flaxseed: a potential treatment for lupus nephritis. Kidney Int 1995; 48(2): 475-480.
185. Mori TA, Vandongen R, Mahanian F, Douglas A. Plasma lipid levels and platelet and neutrophil function in patients with vascular disease following fish oil and olive oil supplementation. Metabolism 1992; 41(10): 1059-1067.
186. Codde JP, Vandongen R, Mori TA, Beilin LJ, Hill KJ. Can the synthesis of platelet-activating factor, a potent vasodilator and pro-aggregatory agent, be altered by dietary marine oils? Clin Exp Pharmacol Physiol 1987; 14(3): 197-202.
187. Mori TA, Beilin LJ, Burke V, Morris J, Ritchie J. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997; 17(2): 279-286.
188. Bankey PE, Billiar TR, Wang WY, Carlson A, Holman RT, Cerra FB. Modulation of Kupffer cell membrane phospholipid function by n-3 polyunsaturated fatty acids. J Surg Res 1989; 46(5): 439-444.
189. Sperling RI, Benincaso AI, Knoell CT, Larkin JK, Austen KF, Robinson DR. Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. J Clin Invest 1993; 91(2):651-660.
190. Chakrabarti R, Hubbard NE, Lim D, Erickson KL. Alteration of platelet-activating factor-induced signal transduction in macrophages by n-3 fatty acids. Cell Immunol 1997; 175(1): 76-84.
191. Koussissis S, Semidalas CE, Hadzistavrou EC, Kalyvas V, Antonopoulou S, Demopoulos CA. PAF antagonists in food: isolation and identification of paf antagonists in honey and wax. Revue Francaise des Corps Gras 1994; 5/ 6: 127.
192. Antonopoulou S, Semidalas CE, Koussissis S, Demopoulos CA. Platelet-activating factor (PAF) antagonists in foods: A study of lipids with PAF or anti-PAF-like activity in cow's milk and yogurt. J Agric Food Chem 1996; 44(10): 3047-3051.
193. Koussissis S, Semidalas CE, Antonopoulou S, Kapoulas VM, Demopoulos CA, Kalyvas V. PAF antagonists in food: isolation and identification of paf antagonists in virgin olive oil. Revue Francaise des Corps Gras 1994; 9/ 10:323.
194. Karantonis HC, Antonopoulou S, Demopoulos CA. Antithrombotic lipid minor constituents from vegetable oils. Comparison between olive oils and others. J Agric Food Chem 2002; 50(5): 1150-1160.
195. Karantonis HC, Zabetakis I, Nomikos T, Demopoulos CA. Antiatherogenic properties of lipid minor constituents from seed oils. J Sci Food Agric 2003; 83(12): 1192-1204.
196. Rementzis J, Antonopoulou S, Argyropoulos D, Demopoulos CA. Biologically active lipids from S. scombrus. Adv Exp Med Biol 1996; 416: 65-72.
197. Panayiotou A, Samartzis D, Nomikos T, et al. Lipid fractions with aggregatory and antiaggregatory activity toward platelets in fresh and fried cod (Gadus morhua): correlation with platelet-activating factor and atherogenesis. J Agric Food Chem 2000; 48(12): 6372-9.
198. Nomikos T, Karantonis HC, Skarvelis C, Demopoulos CA, Zabetakis I. Antiatherogenic properties of lipid fractions of raw and fried fish. Food Chemistry 2006; 96(1): 29-35.
199. Fragopoulou E, Nomikos T, Antonopoulou S, Mitsopoulou CA, Demopoulos CA. Separation of biologically active lipids from red wine. J Agric Food Chem 2000; 48(4): 1234-8.
200. Fragopoulou E, Nomikos T, Tsantila N, Mistopoulou A, Zabetakis I, Demopoulus CA. Biological activity of total lipids from red and white wine/must. J Agric Food Chem 2001; 49(11): 5186-5193.
201. Fragopoulou E, Antonopoulou S, Demopoulos CA. Biologically active lipids with antiatherogenic properties from white wine and must. J Agric Food Chem 2002; 50(9): 2684-2694.
202. Fragopoulou E, Antonopoulou S, Nomikos T, Demopoulos CA. Structure elucidation of phenolic compounds from red/white wine with antiatherogenic properties. Biochim Biophys Acta 2003; 1632(1-3): 90-9.
203. Kristensen SD, Iversen AM, Schmidt EB. n-3 polyunsaturated fatty acids and coronary thrombosis. Lipids 2001; 36 Suppl: S79-82.
204. Karantonis HC, Fragopoulou E, Antonopoulou S, Rementzis J, Phenekos C, Demopoulos CA. Effect of fast-food Mediterranean-type diet on type 2 diabetics and healthy human subjects' platelet aggregation. Diabetes Res Clin Pract 2006; 72(1): 33-41.
205. Antonopoulou S, Fragopoulou E, Karantonis HC, et al. Effect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitus. J Med Food 2006; 9(3): 356-362.
206. Tzeng SH, Ko WC, Ko FN, Teng CM. Inhibition of platelet aggregation by some flavonoids. Thromb Res 1991; 64(1):91-100.
207. Lindahl M, Tagesson C. Selective inhibition of group II phospholipase A2 by quercetin. Inflammation 1993; 17(5):573-582.
208. Gil B, Sanz MJ, Terencio MC, et al. Effects of flavonoids on Naja naja and human recombinant synovial phospholipases A2 and inflammatory responses in mice. Life Sci 1994; 54(20): L333-8.
209. Yanoshita R, Chang HW, Son KH, Kudo I, Samejima Y. Inhibition of lysoPAF acetyltransferase activity by flavonoids. Inflamm Res 1996; 45(11): 546-9.
210. Balestrieri ML, Castaldo D, Balestrieri C, Quagliuolo L, Giovane A, Servillo L. Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress. J Lipid Res 2003; 44(2): 380-7.
211. Sagesaka YM, Uemura T, Watanabe N, Sakata K, Uzawa J. A new glucuronide saponin from tea leaves (Camellia sinensis var. sinensis). Biosci Biotechnol Biochem 1994; 58(11): 2036-2040.
212. Sugatani J, Fukazawa N, Ujihara K, et al. Tea polyphenols inhibit acetyl- CoA:1-alkyl-sn-glycero-3-phosphocholine acetyltransferase (a key enzyme in platelet-activating factor biosynthesis) and platelet-activating factor-induced platelet aggregation. Int Arch Allergy Immunol 2004; 134(1): 17-28.
213. Andrikopoulos NK, Antonopoulou S, Kaliora AC. Oleuropein inhibits LDL oxidation induced by cooking oil flying by-products and platelet aggregation induced by platelet-activating factor. Food Sci Technol 2002; 35(6): 479-484.
214. Fragopoulou E, Nomikos T, Karantonis HC, et al. Biological activity of acetylated phenolic compounds. J Agric Food Chem 2007; 55(1): 80-9.
215. Balestrieri C, Felice F, Piacente S, et al. Relative effects of phenolic constituents from Yucca schidigera Roezl. bark on Kaposi's sarcoma cell proliferation, migration, and PAF synthesis. Biochem Pharmacol 2006; 71(10): 1479-1487.
216. Shigematsu S, Ishida S, Hara M, et al. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med 2003; 34(7): 810-7.
217. Barthomeuf C. Inhibition of SIP-induced angiogenesis, metastasis and inflammation by dietary polyphenols. Free Radic Biol Med 2007; 42(2): 312-3.
218. Shah BH, Nawaz Z, Pertani SA, et al. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem Pharmacol 1999; 58(7): 1167-1172.
219. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995; 55(2): 259-266.
220. Heber D, Lu QY. Overview of mechanisms of action of lycopene. Exp Biol Med (Maywood) 2002; 227(10): 920-3.
221. Balestrieri ML, De Prisco R, Nicolaus B, et al. Lycopene in association with alpha-tocopherol or tomato lipophilic extracts enhances acyl-platelet-activating factor biosynthesis in endothelial cells during oxidative stress. Free Radic Biol Med 2004; 36(8): 1058-1067.
222. Pritchard KA, Greco NJ, Panganamala RV. Effect of dietary vitamin E on the production of platelet 12-hydroxyeicosatetraenoic acid (12-HETE). Thromb Haemost 1986; 55(1): 6-7.
223. Violi F, Pratico D, Ghiselli A, et al. Inhibition of cyclooxygenase-independent platelet aggregation by low vitamin E concentration. Atherosclerosis 1990; 82(3): 247-252.
224. Kakishita E, Suehiro A, Oura Y, Nagai K. Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood. Thromb Res 1990; 60(6): 489-499.
225. Yoshikawa T, Yoshida N, Manabe H, Terasawa Y, Takemura T, Kondo M. alpha-Tocopherol protects against expression of adhesion molecules on neutrophils and endothelial cells. Biofactors 1998; 7(1-2): 15-9.
226. Choi JH, Chung WJ, Han SJ, et al. Selective involvement of reactive oxygen intermediates in platelet-activating factor-mediated activation of NF-kappaB. Inflammation 2000; 24(5): 385-398.
227. Feldman C, Anderson R, Theron AJ, et al. Vitamin E attenuates the injurious effects of bioactive phospholipids on human ciliated epithelium in vitro. Eur Respir J 2001; 18(1): 122-9.
228. Lloberas N, Torras J, Herrero-Fresneda I, et al. Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment. FASEB J 2002; 16(8): 908-910.
229. Lehr HA, Weyrich AS, Saetzler RK, et al. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J Clin Invest 1997; 99(10): 2358-2364.
230. Teng CM, Li HL, Wu TS, Huang SC, Huang TF. Antiplatelet actions of some coumarin compounds isolated from plant sources. Thromb Res 1992; 66(5): 549-557.
231. Tsuchiya H, Sato M, Watanabe I. Antiplatelet activity of soy sauce as functional seasoning. J Agric Food Chem 1999; 47(10): 4167-4174.
232. Apitz-Castro R, Cabrera S, Cruz MR, Ledezma E, Jain MK. Effects of garlic extract and of three pure components isolated from it on human platelet aggregation, arachidonate metabolism, release reaction and platelet ultrastructure. Thromb Res 1983; 32(2): 155-169.
233. Apitz-Castro R, Jain MK, Bartoli F, Ledezma E, Ruiz MC, Salas R. Evidence for direct coupling of primary agonist-receptor interaction to the exposure of functional IIb-IIIa complexes in human blood platelets. Results from studies with the antiplatelet compound ajoene. Biochim Biophys Acta 1991; 1094(3): 269-280.
234. Lim H, Kubota K, Kobayashi A, Seki T, Ariga T. Inhibitory effect of sulfur-containing compounds in Scorodocarpus borneensis Beco on the aggregation of rabbit platelets. Biosci Biotechnol Biochem 1999; 63(2): 298-301.
235. Morris J, Burke V, Mori TA, Vandongen R, Beilin LJ. Effects of garlic extract on platelet aggregation: a randomized placebo-controlled double-blind study. Clin Exp Pharmacol Physiol 1995; 22(6-7): 414-7.
236. Dorsch W, Scharff J, Bayer T, Wagner H. Antiasthmatic effects of onions. Prevention of platelet-activating factor induced bronchial hyperreactivity to histamine in guinea pigs by diphenylthiosulfinate. Int Arch Allergy Appl Immunol 1989; 88(1-2): 228-230.
237. Cao YZ, Cohen ZS, Weaver JA, Sordillo LM. Selenium modulates 1-O- alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) biosynthesis in bovine aortic endothelial cells. Antioxid Redox Signal 2001; 3(6): 1147-1152.
238. Corl CM, Cao YZ, Cohen ZS, Sordillo LM. Oxidant stress enhances Lyso-PAF-AcT activity by modifying phospholipase D and phosphatidic acid in aortic endothelial cells. Biochem Biophys Res Commun 2003; 302(3): 610-4.